Christoffer Gebhardt

Christoffer Gebhardt is a Professor at the University Medical Center Hamburg-Eppendorf (UKE), affiliated with the Medical Faculty and the Clinic and Polyclinic for Dermatology and Venereology. His research focuses on melanoma, immunotherapy, and dermatological oncology, with extensive contributions to understanding biomarkers and treatment responses in skin cancer patients. He actively participates in numerous clinical trials and collaborative research efforts within the European dermatological oncology community.

Professor Gebhardt's research interests center on melanoma biology and treatment, particularly examining biomarkers that predict response to immune checkpoint inhibitors. His work spans from basic mechanisms of immunotherapy resistance to real-world clinical applications, with special emphasis on liquid biopsy techniques, coagulation markers as predictors of treatment response, and sex-specific differences in melanoma outcomes. His research bridges laboratory findings with clinical practice, aiming to improve personalized treatment approaches for melanoma patients.

His publication record demonstrates a strong focus on translational research in melanoma and skin cancer, with recent work highlighting the importance of biomarkers like D-dimers, complement factors, and circulating tumor DNA in predicting treatment response. Gebhardt's research increasingly explores the integration of novel immunotherapies and targeted treatments, with particular attention to real-world evidence from large patient registries like ADOREG.

Professor Gebhardt is actively involved in major professional organizations including the European School of Dermato-Oncology, the Working Group for Dermatological Oncology (ADO), and the European Liquid Biopsy Society. He regularly participates in and organizes key conferences such as the German Skin Cancer Congress and contributes to editorial activities for journals including J DTSCH DERMATOL GES and J EUR ACAD DERMATOL.